Bristol Myers Squibb (NYSE:BMY) Stock Rating Upgraded by Barclays

Bristol Myers Squibb (NYSE:BMY) was upgraded by stock analysts at Barclays to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

A number of other research firms have also recently commented on BMY. Truist Financial set a $65.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, December 3rd. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Citigroup upped their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $57.00 price target (up previously from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $60.19.

Bristol Myers Squibb Trading Up 0.6%

Shares of NYSE:BMY opened at $60.66 on Thursday. The company has a market capitalization of $123.53 billion, a PE ratio of 17.58, a P/E/G ratio of 0.17 and a beta of 0.29. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $63.33. The business’s fifty day simple moving average is $56.22 and its 200-day simple moving average is $49.97.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter last year, the company earned $1.67 earnings per share. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts predict that Bristol Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bristol Myers Squibb

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Gateway Investment Advisers LLC grew its stake in Bristol Myers Squibb by 10.0% in the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after purchasing an additional 10,284 shares in the last quarter. CWA Asset Management Group LLC grew its position in Bristol Myers Squibb by 25.9% in the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after buying an additional 30,909 shares in the last quarter. Commonwealth Retirement Investments LLC increased its stake in shares of Bristol Myers Squibb by 24.6% during the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock valued at $2,740,000 after acquiring an additional 11,690 shares during the period. Stephens Inc. AR lifted its holdings in shares of Bristol Myers Squibb by 13.5% in the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after buying an additional 32,476 shares during the period. Finally, Railway Pension Investments Ltd lifted its stake in Bristol Myers Squibb by 3.7% during the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock valued at $51,396,000 after purchasing an additional 40,300 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays initiated U.S. large‑cap biopharma coverage and included Bristol‑Myers Squibb among four preferred picks, arguing the sector could regain investor attention and highlighting BMY as a top choice. This institutional endorsement likely helped buying interest. Barclays launches U.S. biopharma coverage with four preferred picks
• Positive Sentiment: BMY reported completion of a mavacamten safety‑extension study update, which clarifies the long‑term safety profile for its hypertrophic cardiomyopathy program — a de‑risking event for a later‑stage asset and a potential long‑term revenue driver. BMY’s Mavacamten Safety Extension Wraps Up
• Positive Sentiment: Analyst/commentary pieces highlight BMY’s oncology franchise and new drug launches, noting cost cuts and a stronger 2026 outlook versus peers — reinforcing confidence in revenue stability and medium‑term growth. Bristol‑Myers Squibb: Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Comparative analyst coverage (Zacks/Money pieces) argues BMY edges Merck in the 2026 setup due to product launches and cost actions — a relative positive versus peers but not new company‑specific catalysts. Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
• Neutral Sentiment: Coverage discussing an Iberdomide regulatory review and an AI partnership adds new angles to BMY’s mid‑cycle outlook; informative for pipeline expectations but not an immediate earnings swing. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Negative Sentiment: Zacks Research issued a series of downward revisions to several near‑term EPS estimates (notably Q1/Q2 2026 and FY2027 trims), which introduces caution around short‑term earnings momentum and could cap upside until upcoming results confirm guidance.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.